<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369577</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-201</org_study_id>
    <secondary_id>004-201</secondary_id>
    <nct_id>NCT00369577</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine in Agitation (Proof of Concept)</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the
      treatment of acute agitation in schizophrenic patients. The study will be conducted in 120
      agitated schizophrenic patients - either newly admitted to a hospital setting or a research
      unit for acute agitation or already in hospital for chronic underlying conditions. Patients
      meeting entry criteria will be randomized to one of two doses of Staccato Loxapine or to
      Staccato Placebo. Following administration of study drug, assessment of agitation state will
      be conducted at serial time points using standard agitation scales over a 24 hour period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS-EC Change From Baseline</measure>
    <time_frame>2 hours</time_frame>
    <description>The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BARS Change From Baseline After Drug Treatment</measure>
    <time_frame>2 hours</time_frame>
    <description>Change from baseline on the Behavioral Activity Rating Scale (BARS) ranging from 1 to 7 where: 1 = difficult or unable to rouse, 2 = asleep but responds normally to verbal or physical contact, 3 = drowsy, appears sedated, 4 = quiet, and awake (normal level of activity), 5 = signs of overt (physical or verbal) activity, calms down with instructions, 6 = extremely or continuously active, not requiring restraint, 7 = violent, requires restraint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions-Improvement Scale (CGI-I) After Drug Administration</measure>
    <time_frame>2 hours</time_frame>
    <description>Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I Responders</measure>
    <time_frame>2 hours</time_frame>
    <description>Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled Staccato Placebo, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Loxapine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Loxapine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>Inhaled Placebo, single dose</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <other_name>Staccato Loxapine Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Loxapine 5 mg</intervention_name>
    <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
    <arm_group_label>Inhaled Loxapine 5 mg</arm_group_label>
    <other_name>Inhaled Staccato Loxapine 5 mg</other_name>
    <other_name>ADASUVE 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Loxapine 10 mg</intervention_name>
    <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
    <arm_group_label>Inhaled Loxapine 10 mg</arm_group_label>
    <other_name>Inhaled Staccato Loxapine 10 mg</other_name>
    <other_name>ADASUVE 10 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients between the ages of 18 to 65 years, inclusive.

          2. Patients who have met DSM-IV criteria for schizophrenia, schizophreniform disorder, or
             schizoaffective disorder.

          3. Patients who are judged to be clinically agitated at Baseline with a total score of ≥
             14 on the 5 items (poor impulse control, tension, hostility, uncooperativeness, and
             excitement) comprising the PANSS Excited Component (PEC).

          4. Patients who have a value of ≥ 4 (out of 7) on at least 1 of the 5 items on the PANSS
             Excited Component.

          5. Patients who read and understand English and provide written informed consent.

          6. Patients who are in good general health prior to study participation as determined by
             a detailed medical history, physical examination, 12-lead ECG, blood chemistry
             profile, hematology, urinalysis and in the opinion of the Principal Investigator.

          7. Female participants, if of child-bearing potential and sexually active, and male
             participants, if sexually active with a partner of child-bearing potential, who agree
             to use a medically acceptable and effective birth control method throughout the study
             and for one week following the end of the study. Medically acceptable methods of
             contraception that may be used by the participant and/or his/her partner include
             abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine
             device (IUD), condom with foam or spermicide, vaginal spermicidal suppository,
             surgical sterilization and progestin implant or injection. Prohibited methods include:
             the rhythm method, withdrawal, condoms alone, or diaphragm alone.

        Exclusion Criteria:

          1. Patients with agitation caused by acute intoxication must be excluded. Positive
             identification of non-prescription drugs during urine screening excludes the subject.

          2. Patients treated with benzodiazepines or other hypnotics or oral or short-acting
             intramuscular antipsychotics within 4 hours prior to study drug administration must be
             excluded.

          3. Patients treated with injectable depot neuroleptics within one dose interval prior to
             study drug administration must be excluded.

          4. Patients with a history of allergic reactions to loxapine or amoxapine must be
             excluded.

          5. Female patients who have a positive pregnancy test at screening or are breastfeeding
             must be excluded.

          6. Patients who have Parkinson's disease, hydrocephalus, seizure disorder, or history of
             significant head trauma must be excluded.

          7. Patients with laboratory or ECG abnormalities considered clinically significant by the
             investigator or qualified designee that would have clinical implications for the
             patient's participation in the study must be excluded.

          8. Patients with serious and unstable illnesses including current hepatic, renal,
             gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and
             congestive heart failure), endocrinologic, neurologic (including stroke, transient
             ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and
             meningitis), or hematologic disease must be excluded.

          9. Patients who have a history of acute or chronic pulmonary disease that precludes
             administration of Staccato Loxapine (asthma, bronchitis, emphysema) must be excluded.

         10. Patients who have received an investigational drug within 30 days prior to the current
             agitation episode must be excluded.

         11. Patients who are considered by the investigator, for any reason, to be an unsuitable
             candidate for receiving loxapine, or unable to use the inhalation device, must be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Zimbroff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Clinical Research Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Clinical Research Medical Group, 1317 West Foothill Blvd, Suite 200,</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, Spyker DA, Cassella JV. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 Oct;72(10):1313-21. doi: 10.4088/JCP.10m06011yel.</citation>
    <PMID>21294997</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2006</study_first_submitted>
  <study_first_submitted_qc>August 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>May 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2018</results_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Agitation</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 19 centers between Sep-2006 and Jan-2007. Patients recruited for screening were: 1) admitted to a hospital or research unit with acute agitation, 2) inpatients being treated for chronic underlying conditions who presented with acute agitation, and 3) patients with agitation treated in a psychiatric ED.</recruitment_details>
      <pre_assignment_details>Pre-Treatment Period was defined as the period immediately prior to dosing in which screening procedures and inclusion/exclusion criteria were used to evaluate all patients for eligibility to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo, single dose</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Loxapine 5 mg</title>
          <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
        </group>
        <group group_id="P3">
          <title>Inhaled Loxapine 10 mg</title>
          <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo, single dose</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Loxapine 5 mg</title>
          <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
        </group>
        <group group_id="B3">
          <title>Inhaled Loxapine 10 mg</title>
          <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="7.7"/>
                    <measurement group_id="B2" value="40.8" spread="7.45"/>
                    <measurement group_id="B3" value="39.3" spread="8.77"/>
                    <measurement group_id="B4" value="41.2" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PANSS-EC Change From Baseline</title>
        <description>The Positive and Negative Syndrome Scale–Excited Component (PANSS–EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.</description>
        <time_frame>2 hours</time_frame>
        <population>The ITT population consisted of all patients who took any study medication and had both baseline data and at least 1 efficacy assessment after the. Any observation recorded after the use of rescue medication was censored and subject to the last observation carried forward algorithm.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo, single dose</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 5 mg</title>
            <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS-EC Change From Baseline</title>
          <description>The Positive and Negative Syndrome Scale–Excited Component (PANSS–EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.</description>
          <population>The ITT population consisted of all patients who took any study medication and had both baseline data and at least 1 efficacy assessment after the. Any observation recorded after the use of rescue medication was censored and subject to the last observation carried forward algorithm.</population>
          <units>PANSS units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.98" spread="4.13"/>
                    <measurement group_id="O2" value="-6.71" spread="5.14"/>
                    <measurement group_id="O3" value="-8.56" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0880</p_value>
            <p_value_desc>p-values (adjusted) using Dunnett's t-test in main effects ANCOVA model</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>p-values (adjusted) using Dunnett's t-test in main effects ANCOVA model</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BARS Change From Baseline After Drug Treatment</title>
        <description>Change from baseline on the Behavioral Activity Rating Scale (BARS) ranging from 1 to 7 where: 1 = difficult or unable to rouse, 2 = asleep but responds normally to verbal or physical contact, 3 = drowsy, appears sedated, 4 = quiet, and awake (normal level of activity), 5 = signs of overt (physical or verbal) activity, calms down with instructions, 6 = extremely or continuously active, not requiring restraint, 7 = violent, requires restraint.</description>
        <time_frame>2 hours</time_frame>
        <population>All patients receiving experimental treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo, single dose</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 5 mg</title>
            <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>BARS Change From Baseline After Drug Treatment</title>
          <description>Change from baseline on the Behavioral Activity Rating Scale (BARS) ranging from 1 to 7 where: 1 = difficult or unable to rouse, 2 = asleep but responds normally to verbal or physical contact, 3 = drowsy, appears sedated, 4 = quiet, and awake (normal level of activity), 5 = signs of overt (physical or verbal) activity, calms down with instructions, 6 = extremely or continuously active, not requiring restraint, 7 = violent, requires restraint.</description>
          <population>All patients receiving experimental treatment</population>
          <units>BARS Score, Change from Baseline, units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.930" spread="0.936"/>
                    <measurement group_id="O2" value="-1.53" spread="1.38"/>
                    <measurement group_id="O3" value="-2.02" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0583</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions-Improvement Scale (CGI-I) After Drug Administration</title>
        <description>Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.</description>
        <time_frame>2 hours</time_frame>
        <population>All patients receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo, single dose</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 5 mg</title>
            <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions-Improvement Scale (CGI-I) After Drug Administration</title>
          <description>Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.</description>
          <population>All patients receiving treatment</population>
          <units>CGI-I Units (7=worse, 1=better)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="0.932"/>
                    <measurement group_id="O2" value="2.53" spread="1.10"/>
                    <measurement group_id="O3" value="2.28" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-I Responders</title>
        <description>Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)</description>
        <time_frame>2 hours</time_frame>
        <population>All patients treated</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo, single dose</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 5 mg</title>
            <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-I Responders</title>
          <description>Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)</description>
          <population>All patients treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent through 30 days after last treatment</time_frame>
      <desc>Adverse events observed by the Investigator or study personnel during study assessments or when volunteered by the patient were recorded on the Adverse Event CRF. The severity of the AE and relationship to study drug was determined by the investigator. Medications used to treat the adverse event were recorded on the Concomitant Medication CRF.</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo, single dose</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Loxapine 5 mg</title>
          <description>Inhaled Staccato Loxapine 5 mg, single dose</description>
        </group>
        <group group_id="E3">
          <title>Inhaled Loxapine 10 mg</title>
          <description>Inhaled Staccato Loxapine 10 mg, single dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (version 8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <description>A 43 year-old white male with a history of schizophrenia and intravenous drug abuse (heroin and cocaine) randomized to receive placebo, was found dead on the bathroom floor next to an empty syringe 6 days after treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of schizophrenia</sub_title>
                <description>A 23 year-old male with schizophrenia, randomized to receive Loxapine 10 mg, was hospitalized 14 days later for exacerbation of schizophrenia, agitation, noncompliance with medication taking and response to internal stimuli.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of hypertension</sub_title>
                <description>A 48 year-old m with schizophrenia on treatment for hypertension received Loxapine 5 mg. While being followed up as an out-patient (11 days later), he developed worsening hypertension (BP 210/130), was hospitalized, treated, and D/C the next day</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because of the need to provide informed consent, the types of patients enrolled in the study may not have been representative of the most severely agitated patients who present for emergency care.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

